Benjamin Porter-Brown

506 total citations
10 papers, 394 citations indexed

About

Benjamin Porter-Brown is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Benjamin Porter-Brown has authored 10 papers receiving a total of 394 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Rheumatology, 5 papers in Immunology and 4 papers in Hematology. Recurrent topics in Benjamin Porter-Brown's work include Rheumatoid Arthritis Research and Therapies (8 papers), Autoimmune and Inflammatory Disorders Research (4 papers) and Psoriasis: Treatment and Pathogenesis (2 papers). Benjamin Porter-Brown is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (8 papers), Autoimmune and Inflammatory Disorders Research (4 papers) and Psoriasis: Treatment and Pathogenesis (2 papers). Benjamin Porter-Brown collaborates with scholars based in United Kingdom, Germany and United States. Benjamin Porter-Brown's co-authors include Liz Thompson, Maxime Dougados, Olivier Harari, Joachim Sieper, Anthony Sebba, Ronald van Vollenhoven, Andrea Rubbert‐Roth, Francis Donaldson, Pavel Napalkov and Mark C. Genovese and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Seminars in Arthritis and Rheumatism.

In The Last Decade

Benjamin Porter-Brown

10 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benjamin Porter-Brown United Kingdom	7	264	160	142	51	48	10	394
Yasuhiko Kita Japan	12	233 0.9×	166 1.0×	75 0.5×	25 0.5×	40 0.8×	23	402
Kanzo Amano Japan	8	242 0.9×	117 0.7×	82 0.6×	49 1.0×	49 1.0×	10	450
Aarat Patel United States	8	158 0.6×	97 0.6×	52 0.4×	32 0.6×	19 0.4×	16	297
J. Léone France	7	129 0.5×	75 0.5×	103 0.7×	21 0.4×	25 0.5×	13	313
Nashla Barroso United States	4	107 0.4×	109 0.7×	48 0.3×	58 1.1×	28 0.6×	7	324
Naoshi Nishina Japan	11	242 0.9×	155 1.0×	86 0.6×	57 1.1×	39 0.8×	22	479
H-P Tony Germany	9	242 0.9×	174 1.1×	69 0.5×	15 0.3×	23 0.5×	23	381
M. Luc France	5	294 1.1×	75 0.5×	92 0.6×	15 0.3×	15 0.3×	9	423
Elisa Marocchi Italy	7	204 0.8×	143 0.9×	84 0.6×	38 0.7×	16 0.3×	8	337
Sau Mei Tse China	10	314 1.2×	125 0.8×	57 0.4×	51 1.0×	16 0.3×	18	372

Countries citing papers authored by Benjamin Porter-Brown

Since Specialization

Citations

This map shows the geographic impact of Benjamin Porter-Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Porter-Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Porter-Brown more than expected).

Fields of papers citing papers by Benjamin Porter-Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Porter-Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Porter-Brown. The network helps show where Benjamin Porter-Brown may publish in the future.

Co-authorship network of co-authors of Benjamin Porter-Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Porter-Brown. A scholar is included among the top collaborators of Benjamin Porter-Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Porter-Brown. Benjamin Porter-Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Pardeo, Manuela, Jianmei Wang, Nicolino Ruperto, et al.. (2019). Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. The Journal of Rheumatology. 46(9). 1117–1126. 14 indexed citations

Lok, Laurence S. C., Neda Farahi, Jatinder K. Juss, et al.. (2017). Effects of tocilizumab on neutrophil function and kinetics. European Journal of Clinical Investigation. 47(10). 736–745. 40 indexed citations

Rubbert‐Roth, Andrea, Anthony Sebba, Laura Brockwell, et al.. (2016). Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. RMD Open. 2(1). e000213–e000213. 45 indexed citations

Moots, Robert J., Anthony Sebba, William F. C. Rigby, et al.. (2016). Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Lara D. Veeken. 56(4). kew370–kew370. 66 indexed citations

Curtis, Jeffrey R., Susana Perez‐Gutthann, Samy Suissa, et al.. (2014). Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources. Seminars in Arthritis and Rheumatism. 44(4). 381–388. 38 indexed citations

Vollenhoven, Ronald van, Andrea Rubbert‐Roth, Anthony Sebba, et al.. (2014). 94. Tocilizumab in Patients with Rheumatoid Arthritis and Rates of Malignancy: Results from Long-Term Extension Clinical Trials. Lara D. Veeken. 53(suppl_1). i91–i92. 3 indexed citations

Benedetti, Fabrizio De, Nadina Rubio‐Pérez, Steven I. Goodman, et al.. (2014). A45: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis. Arthritis & Rheumatology. 66(S3). 6 indexed citations

Sieper, Joachim, Benjamin Porter-Brown, Liz Thompson, Olivier Harari, & Maxime Dougados. (2013). Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Annals of the Rheumatic Diseases. 73(1). 95–100. 158 indexed citations

Nash, Peter, S M Hall, Graeme Jones, et al.. (2012). Tofacitinib (cp-690,550), an oral Janus Kinase Inhibitor: Pooled phase 3 analysis in an Australian Rheumatoid Arthritis Study Population. Internal Medicine Journal. 42. 14–14. 6 indexed citations

10.

Sieper, J., Benjamin Porter-Brown, Liz Thompson, Olivier Harari, & Maxime Dougados. (2012). OP0166 Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): Results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. 71. 110–111. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact